UNSPSC 51131908: Hetastarch

This classification denotes a blood substitute, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 875Y4127EA. European Medicines Agency schedules Hetastarch in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14097MIG. Hetastarch generally arises in the molecular formula (C6H7O5)N.C2H5O.H. The term 'hetastarch' is an FDA designation. As of Q4 2014, HETASTARCH remains the US FDA Preferred Term for this commodity. Hetastarch bears US NLM identifiers UMLS ID C0020352 and NCI Concept Code C559.

SMILES: CC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)OC)O)O)OC4C(C(C(C(O4)CO)OC)O)OCCO)O)O)O)O.

UNSPSC 51131908 Hetastarch is a Commodity-tier code for a synthetic colloid plasma volume expander used in emergency medical settings to restore blood volume in trauma and acute blood loss cases. State and local governments procure hetastarch primarily through health departments, hospital systems, emergency medical services agencies, and public health procurement offices. The product is typically acquired as part of routine medical supply contracts or through emergency purchasing to stock ambulances, emergency departments, and trauma centers. Hetastarch competes with other plasma expanders and crystalloid solutions in procurement decisions driven by clinical protocols, shelf life, storage requirements, and cost-per-unit comparisons.

The source provides no recent state and local contract opportunities under this code. Without posted RFPs, RFQs, ITBs, or IFBs to reference, geographic concentration and issuing-body mix cannot be characterized from active procurement activity. The code may see procurement volume through standing medical supply contracts or cooperative purchasing vehicles, but no current solicitations are present in the available data to establish buying patterns, representative jurisdictions, or response timelines.